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Dengue virus infection of certain subsets of the immune system, especially dendritic cells and 
macrophages, is well-established in the literature. On these cells, the virus can use DC-SIGN as a 
receptor. Infection of B lymphocytes is debated, and since B cells upregulate DC-SIGN upon 
activation, we hypothesize that this receptor may also be used for DENV infection of B cells.  
In this thesis, I show that DENV-2 infects primary aB and does not infect resting B cells, 
while DENV-1 infects neither resting nor aB. DENV-2 infection of aB is DC-SIGN dependent. 
Infection of Raji/DC-SIGN cells with DENV-2 is DC-SIGN dependent, while Raji/0 infection is 
observed. Infection is detected via flow cytometry using DENV-specific antibodies: 2H2 for 
DENV-2 infection, and 3H5.1 for DENV-1 infection.  
Statement of Public Health Impact 
 Dengue virus infection incidence has increased in recent decades, and poses a particular 
burden on children in South and Central America. It is known that cells of the immune system 
are directly involved with disease pathogenesis, and so further investigating infection of specific 
immune cells is crucial to understanding how best to prevent negative outcomes of DENV 
infection. B lymphocytes are a key part of the adaptive immune system, and may be infected by 
DENV. My thesis directly investigates this question, and also examines if the C-type lectin DC-
SIGN is the receptor used by the virus for infection. 
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1.0  INTRODUCTION 
Dengue virus (DENV), an enveloped single-stranded RNA virus, causes the most arthropod-
borne infections worldwide (50-100 million per year)
1
. 
 
Approximately 20,000 deaths per year
 
are caused by DENV
2
. Dengue is spread by the Aedes species of mosquito, and unlike other 
flaviriruses that require a non-human animal reservoir to sustain transmission to humans, dengue 
virus is highly adapted to humans and can maintain a mosquito-human-mosquito transmission 
cycle in urban areas
2
. The Aedes aegypti mosquito is the principal urban vector for dengue, and 
is highly adapted to humans. In addition to preferentially laying eggs in artificial containers near 
homes, the female mosquito often feeds from more than one human in the gonotrophic cycle, 
potentially transmitting virus to each
2
.  
The dengue virus is present in four serotypes, DENV-1, -2, -3, and DENV-4, and the 
immune response that develops to infection is serotype-specific: no cross-protective immunity 
develops. This makes vaccine development extremely difficult; vaccines to other flaviriuses have 
been successfully developed
3
 
4
 
5
, while much work has been performed on a DENV vaccine 
without success
6
 
7
.  
The illness that results from human DENV infection is typically subclinical and 
asymptomatic infection, while dengue fever, as well as the more serious diseases of dengue 
hemorrhagic fever (DHF) and dengue shock syndrome (DSS) can develop. DF is an acute febrile 
illness that most commonly occurs in older children and adults, and convalescence can last for 
 2 
several weeks. DHF/DSS are vascular leak syndromes that are thought to be the result of an 
immunological cytokine cascade
2
 which causes increased vascular permeability, leakage, 
hypovolemia, shock, and death if not corrected. There is no specific drug to treat DENV 
infection; treatment is in response to symptomology. If properly managed, DHF/DSS cases have 
a fatality rate of less than 1%
8
. The main risk factors for severe disease include the strain of the 
virus, previous infection with a heterotypic DENV strain, age, and genetic background of the 
person
2
.  
Dengue fever itself is not a new disease, but there has been a marked rise in global 
epidemic dengue in the past 25 years
2
. Contributing to this rise are concurrent human population 
growth, especially in tropical urban centers, increased movement of dengue-infected individuals 
via modern transportation, and a lack of effective and sustained mosquito control strategies
2
. As 
the rate of virus evolution has increased
9
, and homologus recombination has been observed
10
 
11
 
12
 
13
, there is the possibility for the rise of strains with epidemic potential.  
1.1 DENGUE VIRUS 
DENV is a member of the Flaviridae family of viruses. Besides DENV, other notable 
flaviviruses are West Nile virus, yellow fever virus, and hepatitis C virus. All flaviriruses are 
positive-sense, single stranded RNA viruses, each with a genome of approximately 11,000 
nucleotides in length
14
. The spherical virion is composed of three proteins, and is enclosed by a 
lipid envelope
15
. Ten proteins are encoded by the genome in a single open reading frame, of 
which the three structural genes-the capsid (C), premembrane (prM), and envelope (E)-are 
encoded immediately after a brief noncoding region at the 5’ end of the genome. The capsid 
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protein serves to form the nucleocapsid shell that protects the viral genome, while the 
premembrane and envelope proteins are both embedded in the viral envelope. The seven 
nonstructural genes (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) are encoded in the latter 
two thirds of the viral genome. Together, NS3 and NS2B act as a protease, while NS5 serves as 
the RNA-dependent RNA polymerase.  
Upon entry into the host cell, the DENV positive-sense genome is transcribed by host cell 
ribosomes associated with the endoplasmic reticulum
16
. The resulting polyprotein is then cleaved 
by the NS3-NS2B protease
17
 between the NS proteins, and the virus components perform 
replication of the DENV genome from a negative-sense intermediate. Assembly of the virion 
occurs in the membranes of the endoplasmic reticulum, where signal peptidase
18
 cleaves at the 
C-prM, M-E, and E-NS1 junctions. The virions are transported to the Golgi complex, where 
virus maturation occurs. Here, the prM protein is cleaved into M + pr by furin in the acidic trans-
Golgi network
19
. In release from the host cell, prM stabilizes the E protein, preventing fusion of 
the newly-synthesized virion with the host cell. Upon release from the cell, the pr segments 
dissociate from the virion. The release of fully mature virion is dependent on the cell in which 
the virus replicated. Virus propagated on Vero cells, an epithelial cell line, release mainly prM-
containing virions due to inefficient prM cleavage in late-stage maturation
20
, although prM 
containing virions have many of the same characteristics as the fully mature M-containing 
virions.  
The 5’ and 3’ UTR ends of the genome contain highly structured segments, and are 
approximately 100 nucleotides
21
 and 600 nucleotides in length, respectively
22
. Two stem-loop 
structures are found within the capped
23
 5’ UTR – the larger stem loop A (SLA) is the promoter 
recognized by viral RNA polymerase for RNA synthesis
24
. The smaller stem loop B (SLB) 
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contains the 5’UAR (Upstream AUG Region) which is complimentary to a region at the 3’ end of 
the genome
22
. This complementarity is crucial to virus replication, since circularization of the 
genome is required for successful replication
24
.  The 3’ UTR contains a highly conserved 3’ stem 
loop which is essential for virus replication
25
.  
The E protein is a class II fusion receptor, and is also responsible for attachment to host-
cell receptors and virus-mediated cell-membrane fusion
26
. The E protein is organized as 
homodimers on the surface of the virion, and is involved in interaction with cellular receptors as 
well as the membrane fusion process
27
. Each E protein monomer contains three domains – the N-
terminal domain I, the dimerization domain II, and the C-terminal, Ig- like domain III
28
. 
Glycosylation at Asn 153 is necessary for viral infectivity, while glycosylation at Asn 67 is 
important for viral assembly or exit, as well as for interaction with DC-SIGN
29
.  
1.1.1 Dengue infection of human cells 
Flaviviruses enter cells by clathrin-mediated endocytosis, rolling over the surface of the cell to a 
pre-existing clathrin-coated pit
27
. This endocytosis is mediated by at least two virus:cell 
interactions. First, DENV nonspecifically binds to glycosaminoglycan heparin sulfate
30 31
 or the 
structural analogue heparin
27 32
 serves to concentrate virus at the membrane surface for 
interaction with a second, high-affinity receptor
33
. Since heparin sulfate is found on the surface 
of cells in many organs
34
, and the pathology of dengue manifests itself in specific organs, such as 
the liver, other specific receptors must be involved in organ infection.  
DENV has been shown to interact with numerous cellular molecules besides heparin and 
heparin sulfate. In mosquito cells, DENV has been shown to interact with Hsp70, R80, R67, and 
a 45-kDa protein
35
. In human cells, other receptors besides heparin/heparin sulfate have been 
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identified: Hsp90, CD14, GRP78/BiP, and on cells of the myeloid lineage, C-type lectin 
receptors (DC-SIGN, mannose receptor, and CLEC-5)
35
.  
Of the cells of the immune system, the cells of the mononuclear lineage – dendritic cells 
(DCs), macrophages, and monocytes, including Langerhans cells (skin-resident DCs)- are the 
primary target for DENV infection
36
 
37 38
. Upon infection, monocytes and macrophages are 
responsible for the dissemination of virus, and the presence of heterotypic antibodies at 
subneutralizing titers serves to increase uptake of the virus-antibody complex by these cells
39
 in a 
process termed antibody-dependent enhancement (ADE).   
In the antibody response, any antibody directed against DENV will enhance virus 
infection to some extent
40
. Due to the sequence divergence among DENV strains, antibodies are 
of low enough avidity to the novel DENV strain so that complete neutralization is not possible
42
. 
IgM antibodies, those produced against an initial DENV infection, are thought to contribute to 
disease pathogenesis by activating complement through interaction with C3R
41 40
.  The IgG 
antibodies that develop in a secondary infection can bind to the FcR, causing opsonization and an 
increase of virus uptake into the host cell. FcγRIA is found solely on macrophages and dendritic 
cells and preferentially binds monomeric IgG, while the FcγRIIA binds immune complexes and 
is more broadly distributed
40
.  
Mononuclear-lineage cells serve to initiate the innate immune response against DENV 
through the production of interferons (IFNs). Upon infection, both type I (IFN-α, -β) and type II 
(IFN-γ) are secreted upon virus:cell interaction through pattern recognition receptors (i.e., C-type 
lectins [DC-SIGN]
43
, Toll-like receptors
35
). Other immunomodulatory factors are involved in 
DENV clinical progression. The proinflammatory cytokine TNF-α peaks in production at the 
 6 
same time virus production peaks in vitro
44
, and TNF-α secretion by infected macrophages is 
correlated with clinical disease severity
45
. 
There is some controversy surrounding whether B cells are targets for DENV infection. 
Some reports have indicated that B cells are not infected in pools of cells in vitro – either 
PBMCs
46
 or splenic mononuclear cells
47
. In both of these reports, cells of the monocyte lineage 
were the only infected cells. Alternatively, purified primary B cells were able to be productively 
infected by DENV-2 in one report
48
. Different levels of infection were also observed between 
blood donors. DC-SIGN expression is not uniform between individuals, so the differing levels of 
infection could be due to different amounts of receptor availability on each donor’s B cells. In 
vivo, no DENV-infected B cells have been observed during acute infection.  
1.2 B LYMPHOCYTES AND DISEASE PATHOGENESIS 
B lymphocytes are the antibody-secreting cells of the adaptive immune system, secreting 
pathogen-specific antibodies after clonal expansion and subsequent stimulation. Antibodies have 
a crucial role in protection against viral disease. Virus-specific antibodies can bind to the virus 
directly and prevent their entry into cells, neutralizing infectivity
49
, and they can also coordinate 
various effector functions through the Fc (crystallizable fragment) region of the antibody heavy 
chain
50 51
.  
In addition to their antibody-secreting role, B cells also act as antigen-presenting cells. 
Upon encountering antigen, display of antigens internalized via binding to the B cell receptor 
(BCR) is favored over display of antigens acquired via phagocytosis or pinocytosis
51
. 
Internalization of antigen via the BCR also leads to an upregulation of MHCII expression
52
 
53
, 
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facilitating the efficient presentation of antigen to CD4
+
 T cells by activated B cells. Pathogens 
can thus subvert the antigen-presenting nature of B cells in order to alter the action of T cells. 
Several virus infections - HIV
54
 and SIV
55
, as well as EBV
56
 and HHV-8
57
 – downregulate either 
MHC I or II. DENV infection of either K562 or THP-1 cells causes the upregulation of MHC I
58
, 
allowing for infected cells to evade detection by NK cells.  
Since B cells are not lymph-node restricted after activation, they can serve as a vehicle 
for virus transport around the body. In hepatitis C virus (HCV) infection, B cells bound by virus 
in a DC-SIGN dependent manner can infect hepatoma cells in trans
59
.  
1.2.1 DC-SIGN 
The C-type lectin DC-SIGN (Dendritic Cell - Specific Intercellular adhesion molecule 3-
Grabbing Nonintegrin) plays an important role in pathogen-dendritic cell and DC-T cell 
interactions, as well as in DC migration and pathogen uptake
60
. Since DC-SIGN is expressed on 
DCs at the initial site of infection, it is likely an important molecule for DENV infection of cells. 
DC-SIGN is important for the internalization of other pathogens, such as Ebola virus
61
, 
Leishmania amastigotes
62
, hepatitis C virus
63
, human herpesvirus 8
64
, and Mycobacterium 
tuberculosis
65
. DC-SIGN is also important for the trafficking of HIV through the immune 
system. The virus binds to DC-SIGN on mucosal DCs, which then migrate to secondary 
lymphoid organs and transfer the virus in trans to CD4
+
 T cells
66
. DC-SIGN, which is 
upregulated on IL-4, CD40L stimulated B cells
67
, also mediates the trans infection of CD4
+
 T 
cells
68
.   
The DC-SIGN carbohydrate recognition domain (CRD) binds to DENV-2 E 
glycoproteins at Asn 67, and binds to 2 of 3 E molecules in complex on the mature virion, 
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leaving the other E protein free to bind with other receptors
28
. Relating to clinical disease, 
polymorphisms within the DC-SIGN promoter are associated with disease severity
60
.  
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2.0  STATEMENT OF THE PROBLEM 
DENV exerts much of its pathologic effects via infection of cells of the immune system, but little 
work has been done directly on isolated primary B cells to determine if they are a target for 
infection. I hypothesize that B cells are a target for DENV infection in vitro. The majority of the 
literature surrounding DENV infection of human cells does not show infection in B cells
46 47
, but 
one group has shown infection. Lin et al
48
 notes a difference in the infection of B cells between 
blood donors, and since DC-SIGN levels are known to vary amongst individuals, DC-SIGN 
expression may be the cause for this observation. B cells may also be a method for DENV traffic 
through the body, as is observed in HCV infection
59
, contributing to the pathogenesis of disease. 
In this thesis, I will investigate the role of B cells and DC-SIGN in DENV infection.  
2.1 AIM 1- INFECTION OF CELL LINES AND PRIMARY B CELLS BY DENV-2 
Given the controversy surrounding the infection of primary human B cells, I will investigate 
whether B cells are target for DENV-2 infection. Initially, I will perform experiments using the 
Raji cell line, which is a cell line derived from Burkitt lymphoma cells, and also Raji cells that 
have been stably transfected with a DC-SIGN expression plasmid. I show that DC-SIGN is 
important for infection of Raji/DC-SIGN as well as activated B cells. Infection of resting B cells 
is not observed.   
 10 
2.2 AIM  2 – DENV-1 DIFFERENCES IN B CELL INFECTION 
Since DENV is present in 4 serotypes, I next chose to examine if DENV-1 infection of B cells 
differs from that of DENV-2. Using the Hawaii strain
69
, a prototype DENV-1 strain, and again 
using activated and resting B cells, I show that DENV-1 infects neither cell type.  
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3.0  MATERIALS AND METHODS 
3.1 B CELL ISOLATION 
Human blood from anonymous donors was obtained from the Central Blood Bank (Pittsburgh 
PA) and processed within 18 hours of delivery. Blood was spun initially to obtain the buffy coat 
layer, which was then diluted extensively and placed over Ficoll-Hypaque (GE Healthcare). 
PBMCs were then isolated, counted, and frozen in heat-inactivated fetal bovine serum (FCS, 
GemCell) with 10% DMSO (Sigma). Upon use, frozen cells were quickly thawed, washed once 
in either RPMI-1640 (Gibco) +10% FCS + antibiotics (100 U/mL penicillin, 100 μg/mL 
streptomycin, 50 μg/mL gentamicin, 0.5 μg/mL amphotericin B) or Hank’s Balanced Salt 
Solution (Gibco) and purified. B cells were then isolated using negative selection using the B 
Cell Isolation Kit II (Miltenyi Biotec), or by negative selection using the CD14 Microbeads 
(Miltenyi Biotec), and then positive selection using CD19 Microbeads (Miltenyi Biotec). After 
isolation, B cells were counted and either used immediately as resting B cells, or activated for 48 
hours in RPMI+10% FCS + antibiotics supplemented with CD40L (1 μg/mL, Enzo) and 
recombinant human IL-4 (rH IL-4, 1*10
3
 U/mL, R&D Systems) for use as activated B cells. 
Cells were incubated in a humid chamber at 37°C supplemented with 5% CO2.  
 12 
3.2 CELL CULTURE 
Vero cells (ATCC CCL-81) were cultured in Eagles Minimum Essential Media (EMEM, Lonza) 
supplemented with 10% FCS. Cells were split upon reaching confluence using 0.05% 
trypsin/EDTA (Gibco), and were re-seeded at a concentration of 4*10
4 
cells/cm
2 
in a T-75 flask 
(Corning).  
Raji cells were obtained from ATCC, Virginia USA. Raji/DC-SIGN cells were a kind gift 
of Dan Littman, NYU School of Medicine. DC-SIGN expression is under the control of MLV 
promoters (plasmid pMX DC-SIGN, NIH AIDS Research & Reference Program). This plasmid 
does not have a selectable marker for eukaryotic cells; an ampicillin resistance cassette is 
encoded for selection of transformed bacteria.  
Cells were maintained in RPMI-1640 supplemented with 10% FCS, and were kept in a 
humidified chamber (37°C, 5% CO2).  
3.3 INFECTION OF CELLS AND BLOCKING OF DC-SIGN 
For infection of cells, virus (DENV-1 Hawaii strain or DENV-2 strain 16681) was added to cells 
resuspended in a minimum volume of media at MOI of either 1.2 (B cell experiments) or 2.4 
(cell lines). The lower viral titer for primary cells was used in order to continue using the same 
pool of virus through the experiment – increasing the titer would have resulted in multiple pools 
being used. Virus stocks were a kind gift of J. Evans and S. McBurney. The virus-cell mixture 
was then incubated with gentle shaking every 15 minutes for a total of 1 hour. After infection, 
cells were pelleted and supernatant samples were placed at -20° for at least 2 hours, then at -80° 
 13 
indefinitely. The cells were then washed twice and used either immediately or placed in the 
incubator for analysis at later time points.  
When DC-SIGN was blocked prior to infection, cells were pelleted, resuspended in a 
minimum volume of cold media, and 20 μg/mL anti-human DC-SIGN (R&D Systems) was 
added. The cell mixture was then placed at 4° for 1 hour, and cells were washed using an excess 
volume of cold media. Cells were then used for infection.  
For infection of adherent Vero cells, virus (DENV-2 strain 16681, gift of Dr. Barratt-
Boyes) was added to 75% confluent Vero cells in a muli-chambered slide. Virus was added in a 
minimal volume, and was allowed to incubate at 37° for 1 hour, at which point cells were 
washed. Fresh media was placed over the cells, and immunofluorescence assay was conducted 
24 hours post infection.  
3.4 FLOW CYTOMETRY 
50,000 cells suspended in PBS were placed in a 96-well V-bottom plate and centrifuged. They 
were then stained with 50 uL of LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Invitrogen) and 
incubated in the dark for 30 minutes. After washing with monoclonal wash buffer (0.22 μm 
filtered PBS + 2% (v/v) FCS + 0.1% (mass/volume) NaN3), cells were resuspended in 100 uL of 
1x permeabilizing solution (BD FACS Permeabilizing Solution 2, prepared in PBS) and again 
allowed to incubate. After washing, cells were resuspended in 200 uL Super Blocking Buffer 
(Pierce, in PBS) and allowed to incubate. After centrifugation, cells were resuspended in 50 uL 
wash buffer, and antibodies were added.  
 14 
 For analysis of infection of Raji or Raji/DC-SIGN cells, the following antibodies were 
added: PE-CD209, Zenon AF680-3H5.1, and Zenon AF594-2H2. Isotype control antibodies 
were also used: PE-IgG2b, Zenon AF680-IgG1, and Zenon AF594-2H2.  
 For analysis of infection of resting or activated B cells, the following antibodies were 
used: PE-CD209, Zenon AF680-3H5.1, Zenon AF594-2H2, APC-CD23, and FITC-CD19. 
Isotype control antibodies were also used: PE-IgG2b, Zenon AF680-IgG1, Zenon AF594-2H2, 
APC-IgG1κ, and FITC-IgG1.  
Again, after 30 minutes incubation in the dark, cells were washed, and resuspended in 
200 uL of 1% paraformaldehyde. The plate was then placed in a covered box at 4° until analysis.  
Compensation controls were prepared on the day of running the samples as follows. One 
drop each of either a negative or positive control bead (BD Biosciences) was added to a 96-well 
V-bottom plate, and 5 uL of antibody was added to the wells containing positive control beads: 
V500-IgG1κ (control for viability dye), PE-CD209, AF700-IFNγ (control for AF680-labeled 
Abs), PE-Texas Red (control for AF 594-labeled Abs), and, for analysis of B cells, APC-CD19 
and FITC-CD23. After incubation for 10 minutes in the dark, the beads were washed, pelleted, 
and resuspended in monoclonal wash buffer. Samples were read on a BD LSRII flow cytometer, 
and data was analyzed using FlowJo (TreeStar Inc.). Figures and statistics (Student’s two-sample 
paired t test) were prepared using Microsoft Excel.  
Antibodies were obtained from the following sources: BD Pharmigen (PE-IgG2b, 
AF700-IFNγ, APC-CD23, FITC-CD19, APC-IgG1κ), BD Biosciences (FITC-IgG1), BD 
Horizon (V500-IgG1κ), R&D Systems (PE-CD209), Invitrogen (Zenon labeling kits), Millipore 
(3H5.1, 2H2), and Sigma-Aldrich (Mouse IgG1 and IgG2a). 
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3.5 IMMUNOFLUORESCENCE ASSAY 
At the same time as isolation for flow cytometry, approximately 5*10
4
 cells were placed onto a 
trypsin-coated glass slide. The cell spot was allowed to dry, and then the slide was placed in PBS 
at 4°C for less than one week. Upon immunostaining, slides were removed from PBS and fixed 
in 2% paraformaldehyde for 15 minutes, washed in PBS, and then permeabilized using 0.1% 
Triton-X 100 (Sigma) for 15 minutes. After washing in PBS, nonspecific sites of the cell were 
blocked using Super Blocking Buffer (Pierce) for 45 minutes, the slide was washed, and then 50 
uL of a 1:10 dilution of hybridoma-produced 2H2 antibody (kind gift from T. Wang) was added 
to each spot. The antibody was allowed to incubate for 1 hour, at which point the slide was 
washed as usual, and then a mixture of 1:500 Alexa Fluor 568 F(ab')2 fragment of goat anti-
mouse IgG (H+L) (Invitrogen) and FITC-CD209 (BD) were mixed in equal volumes, and 
approximately 50 uL of this mix was added to each cell spot and allowed to incubate, again for 1 
hour, in the dark. After washing, slides were mounted using SlowFade Gold with DAPI 
(Invitrogen), and the coverslip was sealed using clear nail polish. Slides were imaged using a 
Nikon Eclipse E600 microscope, and images were collected and layered using MetaMorph 
software (Molecular Devices). Images visualization was minimally enhanced   using Photoshop 
(Adobe).  
3.6 FOCUS FORMING UNIT ASSAY 
Vero cells (ATCC CCL-81) below the 10th passage were plated in a 12-well plate at 7.5x10
4
 
cells per well in 2 mL of EMEM (Lonza) supplemented with 2% FCS. After overnight 
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incubation (5% CO2, 37°), serial dilutions of saved supernatant samples from experiments were 
prepared in EMEM without FCS. Media was removed from the cell plates, and the cells were 
rinsed once with 2 mL PBS. 300 uL of each virus dilution was added to wells in duplicate, and 
the plate was incubated at 37°, 5% CO2 for 1 hour with gentle shaking every 15 minutes. After 1 
hour incubation, the virus dilutions were aspirated from the cells, the plate was washed 2X with 
PBS, and 2 mL of 0.2% methyl cellulose media (500 mL EMEM, 15 mL heat-inactivated FCS, 5 
mL penicillin/streptomycin [100 U/mL penicillin, 100 μg/mL streptomycin], 4 grams methyl 
cellulose) was added to each well. The plates were incubated for 5 days, after which time the 
medium was removed and wells were rinsed 2X with PBS. Cells were then fixed in a 
methanol/acetone mixture (1:1) for 30 minutes, and were then dried for at least 2 hours. Wells 
were then rehydrated with PBS, blocked using a 3% FCS in PBS solution for 30 minutes, and 
250 μL of a 1:450 dilution of 2H2 antibody (Millipore) was then added to each well. Plates were 
placed in a humid chamber on a rotating platform overnight. The following morning, plates were 
rinsed with PBS, and 250 uL of a 1:500 dilution of goat anti-mouse IgG-HRP (Millipore, 
prepared at 0.5 mg/mL) was added to each well and incubated for 1 hour on a rotating platform. 
The wells were rinsed, and 250 μL of TrueBlue Peroxidase Substrate (KPL) was added to each 
well. The plates incubated for 10 minutes in darkness on the rotating platform before removal of 
the substrate, and were then fixed with 1 mL water for 5 minutes. The liquid was removed, and 
plates were allowed to dry overnight before calculating the FFU titer as follows: FFU/mL = 
((#spots in well 1 + #spots in well 2)/2)/((dilution factor)(volume plated (0.3 mL)). Spots were 
counted manually.  
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4.0  RESULTS 
4.1 OPTIMIZATION OF PROTOCOLS 
In initial experiments (data not shown), concern was raised about the ratio of the Zenon kit-
labeled anti-DENV antibody 2H2 to the number of cells. This antibody binds to the prM protein 
of all DENV serotypes. To test this, I performed a dilution series of the labeled antibody on 
DENV-2 infected Vero cells (Figure 1). The antibody preparation was diluted in PBS after 
conjugation. Like in infection of cells and cell lines, infection was performed for 1 hour. After 
infection, cells were washed with PBS and allowed to incubate for 24 hours. No negative control 
was performed for this experiment.  
Although not tested on Vero cells, the 3H5.1 antibody, a DENV-2 E protein specific Ab, 
is also used to detect DENV-2 infection by flow cytometry after labeling with a Zenon kit. From 
these results, 1 μg of Zenon-labeled antibody, either AF680-2H2 or AF594-3H5.1, was used in 
future experiments to detect infection by flow cytometry. Since the Zenon kit instructions are 
written to stain 1x10
5
 cells, and the number of cells used per well for flow cytometry is 0.5x10
5
, 
I used one-half of the Zenon kit’s final volume for staining.  
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Infections were then performed on Raji cells that have been stably transfected with a DC-
SIGN expression plasmid (Raji/DC-SIGN cells). The cells were infected with DENV-2 for 1 
hour, and were assayed at 0, 24, and 48 hours post-infection (hpi) by flow cytometry (Figure 2).  
Mock-infected cells do not stain positive for the DENV-specific antibodies at a level above that  
of the isotype controls (Figure 2A). Cells infected with DENV-2 (Figure 2B) do not stain 
positive for the DENV-specific antibodies at 0 and 24 hpi, but do stain positive for both 2H2 and 
3H5.1 at 48 hpi. The majority of DENV-positive cells (positive for 3H5.1 antibody) also express 
DC-SIGN (Figure 3). DC-SIGN levels slightly decrease in infected cells when compared with 
Figure 1. 1 μg of Zenon AF680-labeled 2H2 antibody gives optimum detection of DENV-2 infection of 
Vero cells.   
DENV-2 infected Vero cells were stained with decreasing amounts of Zenon AF680-labeled 2H2 
antibody (red) for one hour at 24 hours post-DENV infection. Blue = DAPI. A) 1 μg labeled 2H2, B) 
0.5 μg labeled 2H2, C) 0.25 μg labeled 2H2, D) 0.125 μg labeled 2H2. 
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their mock-infected counterparts. The combination of 2H2 and DC-SIGN (CD209) was not 
tested.  
Although not directly tested, this experiment indicates that the infection of Raji/DC-
SIGN cells by DENV-2 may be DC-SIGN dependent. Given these results, the time-points of 0 
and 48 hpi were used for all future experiments. The DC-SIGN expression for the cells was 
relatively low: 42±4.8 percent of cells expressed DC-SIGN. For future work with Raji/DC-SIGN 
cells, another lineage of cells was used that had an average of 80% DC-SIGN expressing cells. 
 
 
Figure 2. DENV-2 infection of Raji/DC-SIGN cells is detected at 48 hpi.  
A) DENV-specific antigens are not detected in mock-infected cells. B) Both the DENV-2 specific 3H5.1 and pan-
DENV 2H2 antibodies bind to DENV-2 infected cells (MOI=2.4) at 48 hours post infection. CD209=DC-SIGN. 
Red, isotype control. Blue, specific antibody. C) Gating strategy – first on singlets (left), then on live cells (right). 
N=1  
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4.2 INFECTION OF RAJI/0 CELLS 
To investigate our hypothesis that the infection of Raji/DC-SIGN cells is in fact DC-SIGN 
dependent, I first infected Raji/0 cells – Raji cells that have not been transfected with a DC-
SIGN expression plasmid (Figure 4).  The mock-infected Raji/0 cells (Figure 4A, Raji/0) have 
significantly different appearances at 48 hpi in regards to the specific antibodies (3H5.1 and 
CD209). Since it appears that the double-negative population at 0 hpi shifts completely to the X-
axis at 48 hpi, no fluorescence is being detected for this cell population, most likely due to 
incorrect addition of antibodies during the staining step of the flow cytometry procedure. This 
experiment was repeated, in order to both confirm the results seen in the DENV-2 infected cell 
population and also to ensure that antibodies were correctly added to all wells. However, analysis 
of these samples was not performed due to all of the cells being dead based on the Live/Dead cell 
Figure 3. DENV-2 infection of Raji/DC-SIGN cells is DC-SIGN dependent.  
Summary table of Figure 2. Values presented = (% positive specific stain - % positive 
isotype control). CD209=DC-SIGN. N=1.  
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stain kit.  Before the flow staining protocol, viability of the cells was approximately 50% by the 
trypan blue exclusion method.  
 
 
From these results, the infection of Raji/0 cells may be DC-SIGN independent, since 
there are no 3H5.1-positive cells that also are positive for DC-SIGN. At 0 hpi, DENV-2 infection 
causes a decrease in DC-SIGN expression. If DENV uses DC-SIGN as a receptor, then the 
binding of a virus and subsequent internalization of virus and receptor would then result in the 
Figure 4. Infection of Raji/0 cells may be DC-SIGN independent.  
A) A) Mock-infected Raji/0 cells (left) or DENV-2 infected Raji/0 cells (right) were stained with isotype control 
antibodies (top row) or specific antibodies (bottom row) against CD209 (DC-SIGN) or the DENV-2 specific 3H5.1. 
B) Graph summarizing the results of A. Values presented = (% positive specific antibody) – (% positive isotype 
control antibody). N=1.  
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reduction of DC-SIGN detection by flow cytometry. The larger issue with this data, however, is 
that nearly 7% of Raji/0 cells are expressing DC-SIGN at 0 hpi. Since the cell line has 
theoretically never come into contact with a DC-SIGN expression plasmid, and Raji cells do not 
express DC-SIGN endogenously, there must have been some contamination of Raji/0 cells with 
Raji/DC-SIGN cells at some point in time. There is no way to selectively eliminate DC-SIGN 
expressing cells from the culture without using cell sorting, so any future work on Raji/0 cells 
should ensure using cells that have had their DC-SIGN expression validated before infection.  
 
4.3 BLOCKING DC-SIGN PRIOR TO INFECTION OF RAJI/DC-SIGN CELLS 
In order to investigate whether the infection of Raji/DC-SIGN cells is DC-SIGN dependent, and 
since the infection of Raji/0 cells is possible, I performed a blocking experiment on Raji/DC-
SIGN cells. Before infection, cells were incubated with an anti-human DC-SIGN  
monoclonal antibody, and were then used for infection (Figure 5).  
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Blocking DC-SIGN with a monoclonal antibody prior to infection greatly reduced the 
detection of DENV-2-specific antigen by the 3H5.1 antibody. At 48 hpi, 80.9% of cells are 
infected by DENV-2, while less than 1% of cells that have been blocked prior to infection are 
DENV-2 positive. This indicates that the infection of Raji/DC-SIGN cells is DC-SIGN 
dependent. Since literature has already been published on this finding
70
, this result validates my 
laboratory methods.   
As was seen with Raji/0 cells (Figure 4), the detected DC-SIGN levels decrease between 
0 and 48 hpi. Putting aside the discussion of why Raji/0 cells are expressing DC-SIGN in the 
first place, the Raji cells may be losing the DC-SIGN expression plasmid with time, since no 
selection marker exists within the plasmid.  
Figure 5. Infection of Raji/DC-SIGN cells by DENV-2 is DC-SIGN dependent. 
A) Flow cytometric plots showing the infection of Raji/DC-SIGN cells at 0 and 48 hpi with blocking DC-SIGN 
prior to infection. Gating is derived from isotype controls. B) and C) IFA of mock-blocked, DENV-2 infected cells 
(B) and blocked, DENV-2 infected cells (C) at 48 hpi.  Arrow=infected cell. N=1. 
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4.4 DENV-2 INFECTION OF PRIMARY RESTING AND ACTIVATED B CELLS 
Since my experimental methodology had been validated in the Raji/DC-SIGN cell line, I next 
moved to using primary resting or activated B cells. The B cells were activated with a cocktail of 
CD40L and IL-4, mimicking CD4
+
 T activation in the germinal center.  
DENV-2 infection was performed on both resting and activated B cells. As in previous 
experiments, analysis was conducted at 0 and 48 hpi. Three independent experiments were 
performed (Figure 6) using B cells from three different blood donors (groups 1, 2, and 3 in 
Figure 6).  
The DC-SIGN expression of rB and aB does not differ significantly (p=0.36) when 
pooled together. Individually, blood donors 1 and 2 do upregulate DC-SIGN upon activation – 
Donor 1 increases DC-SIGN expression in aB compared to rB by 9.1%, Donor 2 by 7.8%. Donor 
3 is unique in that there is very high DC-SIGN expression in rB at 0 hpi (23.8% positive), which 
is decreased at all future timepoints and with activation. Extensive literature has been published 
using the method of activating B cells using the CD40L and IL-4 cocktail that I use here. By 
another marker of activation, CD23, the aB are, in fact, activated when compared with rB 
(p=0.299*10
-8
, Figure 7). A different blood donor was used as a source of B cells for each of the 
three experiments that were conducted.  
In infection of resting B cells (rB) and activated B cells (aB) with DENV-2, resting B 
cells are not infected, while activated B cells are infected. The detection of DENV-2 in activated 
B cells is not statistically significant between the two time-points tested. The difference in 3H5.1 
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expression between infected aB and rB at 48 hpi is mildly significant (p=0.07). Using the focus 
forming unit assay, DENV-2 does not productively replicate in aB, since there is no virus 
detected at 48 hpi in supernatants from infected cells. Another method to analyze the infection of 
cells would be to test the supernatants for an increase in the copy number of (positive-sense) 
genomes by quantitative PCR. Resting B cells are not infected by DENV, and there is no 
statistically significant difference between 3H5.1 detection at 0 hpi and 48 hpi.  
 
Figure 6. DENV-2 does not infect resting B cells, but does infect activated B cells.  
Left column, resting B cells; Right column, activated B cells. Numbers along X-axis represent the 3 separate 
independent experiments conducted, each with a different blood donor. For 3H5.1 and 3H5.1/CD209, values 
presented are % positive over the mock-infected control values for the same antibody. For CD209, values presented 
are the % positive over isotype controls. CD209=DC-SIGN. 
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To fully investigate the role of DC-SIGN as a receptor for DENV-2 infection, I 
performed an experiment in which the cells were pre-incubated with a monoclonal anti-DC-
SIGN antibody. This incubation causes the receptor to be endocytosed, thus making it 
unavailable to both a pathogen and other DENV-specific antibodies. In one experiment, DC-
SIGN was successfully blocked with a monoclonal antibody prior to infection (Figure 8). Ideally, 
the DC-SIGN expression on any DC-SIGN expressing cell would be close to zero percent after 
blocking.  
In this experiment, a low level of DENV was detected at 0 hpi, and this detection 
increased with the blocking of DC-SIGN prior to infection. PRrevious experiments (Figure 5) 
indicated that DC-SIGN was important to DENV-2 infection of Raji/DC-SIGN cells, while the 
increased detection at 0 hpi in aB could indicate that a receptor other than DC-SIGN is also 
important for infection.  
Figure 7. CD23 is upregulated with B cell activation. 
CD23 expression, a marker of B cell activation, in resting B cells (green) and activated B cells (brown) 
at 0 and 48 hpi with various treatments and virus infections. Bars represent the standard error of the 
mean. 
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Here, although DC-SIGN is only reduced by approximately 10%, the downregulation is 
still notable.  This observation is due to the detection of endocytosed or newly-synthesized DC-
SIGN that is made available to the flow cytometry antibody by permeabilization. Performing the 
stain with the anti-DC-SIGN antibody prior to permeabilization would allow for a true 
quantification of the DC-SIGN levels after blocking. This would also allow for a definitive 
statement to be made about if DENV-2 infection of aB is DC-SIGN dependent. As the data 
stands, DC-SIGN is important to DENV-2 infection.  
In order to validate these data, the same blocking experiment was independently repeated 
twice (Figure 9). 
  
Figure 8. DC-SIGN is an important receptor for DENV-2 infection of activated B cells.   
Activated B cells express DC-SIGN (CD209), which is reduced upon blocking with an anti-
DC-SIGN antibody. Data are from one experiment with blood donor number 1.  
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Staining for DC-SIGN after blocking at 0 hpi, approximately 2 hours post-blocking, 
should result in a strong reduction in DC-SIGN levels when compared to non-blocked cells. This 
is not observed (Figure 9), and DC-SIGN levels are actually slightly higher in blocked cells at 0 
hpi than in the mock blocked cells (4.8% as compared to 3.9% DC-SIGN positive cells, 
respectively). There is not a significant difference in 3H5.1 detection between the two 
timepoints, indicating that the DENV-2 infected cells do not support replication of the virus.  
4.5 DENV-1 INFECTION OF RESTING AND ACTIVATED B CELLS 
In order to compare the differences between DENV serotypes in the infection of B cells, 
infections were also performed using the DENV-1 strain Hawaii (Figure 10). Infections were 
Figure 9. In two experiments, blocking DC-SIGN prior to the infection of activated B 
cells did not reduce DC-SIGN detection as expected.  
Values presented are the average of two independent experiments, using blood donors 2 
and 3. For 3H5.1 and 3H5.1/CD209, values presented are % positive over the mock-
infected control values for the same antibody. For CD209, values presented are % positive 
over isotype control. N=2.  
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performed as previously described in two independent experiments. Infections were not 
performed on Raji/DC-SIGN cells before conducting experiments on primary rB and aB.  
DENV-1 does not infect rB cells at 0 hpi, and the detection of the DENV antigen 2H2 
does not differ significantly between 0 and 48 hpi (p=0.13). DENV-1 does not infect aB, and 
2H2 levels do not significantly increase as they should if infection was present at 48 hpi 
(p=0.15). DC-SIGN expression does not differ significantly between rB and aB (p=0.25). The 
same blood donors for these experiments were used in the infections with DENV-2, and so the 
lack of DC-SIGN upregulation is expected. As in the DENV-2 infections, CD23 expression does 
increase significantly with activation of B cells (p=0.01, Figure 7).  
DC-SIGN expression between infection with DENV-2 (Figure 6) and DENV-1 (Figure 
10) differs. The same blood donors were used in each experiment, and infections with the 
different serotypes of virus were conducted at the same time. Viability between the cell 
populations did not differ. One explanation for this observation could be that the receptor is 
being endocytosed with viral binding and entry, but this is not reflected in the percentage of 
DENV-1 positive cells. 
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Figure 10. DENV-1 does not infect resting or activated B cells.  
Resting B cells, left column;  Activated B cells, right column. Values along X-axis represent the two independent 
experiments conducted with blood from donors 2 and 3. For 2H2 and 2H2/CD209, values  presented are % positive 
over the mock-infected control values for the same antibody. For CD209, values presented are % positive over 
isotype control. CD209=DC-SIGN. 
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5.0  DISCUSSION 
The majority of my thesis comprised of methods validation. Initially, I established the correct 
volume of Zenon kit to visually quantitate DENV-2 infection of Vero cells, and this volume was 
used for all other experiments.  I also established a timepoint at which infection was detected in 
the model system of Raji/DC-SIGN cells, as well as confirming that DENV infection of 
Raji/DC-SIGN cells may be DC-SIGN dependent.  
I also performed experiments on Raji/DC-SIGN cells using DENV-2 to establish 
protocols within the model system. DENV has been shown to fuse to the endosome within 5 
minutes of endocytosis
71
, and others have used various times of incubation (1 hour
72 73 74
, 90 
minutes
46 38 47 48
, 2 hours
75 76
, 4 hours
70
). Incubating the virus with cells for 1 hour is a standard 
procedure in studies of virus infectivity, and was therefore chosen in this study as well. Raji/DC-
SIGN infection by DENV-2 was detected at 48 hpi, and this timepoint was used for all future 
experiments.  The infection of Raji/DC-SIGN cells was eliminated when cells were pre-blocked 
with a monoclonal anti-DC-SIGN antibody. Images of this experiment (Figure 5) demonstrate 
that infection can be visualized via IFA, and that DENV-2 infected cells are also DC-SIGN 
expressing cells. It is interesting to note that there is a low percentage (approximately 25%) of 
DENV-infected cells by IFA, while by flow cytometry, 80.9% of cells were DENV-positive. 
Fundamentally, the detection methods do not differ significantly between these two analysis 
methods, so the same percentage of DENV-infected cells should be noted with each method. 
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Flow cytometry is a more accurate method of protein quantification per cell than IFA, so this 
method is the predominant one presented. Analysis of infection by another method, such as 
detecting nonstructural proteins by Western blot, would have given a clear indication of the 
extent of infection.  
It was observed that DC-SIGN expression decreases with time within the Raji/DC-SIGN 
cell population. DENV-2 infection may cause the downregulation of DC-SIGN expression. 
Receptor downregulation occurs in other viral systems, either as a part of immune evasion 
(HIV
77 
) or as a consequence of infection (measles
78
). DENV may downregulate DC-SIGN in 
order to prevent re-infection of cells that it has just been released from.  
Since Raji cells are used as a model for B lymphocytes, I expected to see similar results 
regarding DENV-2 infection in aB as I did in Raji/DC-SIGN cells. My results indicate that 
DENV-2 infects aB, but that the infection is not statistically significant when compared to rB. 
This may be due to the low DC-SIGN expression in general of the aB. If DENV-2 is indeed 
entering B cells using DC-SIGN as a receptor, as it does in Raji/DC-SIGN cells, then the low 
receptor availability may explain the low percentage of infected aB observed. This supports my 
hypothesis that the infection of B cells is DC-SIGN dependent. In these experiments up to 80% 
of Raji/DC-SIGN cells expressed DC-SIGN, while an average of 15% of aB expressed DC-
SIGN. Since a large part of my research questions are reliant on aB expressing DC-SIGN, this 
relatively low DC-SIGN expression (when compared to Raji/DC-SIGN cells) dampens any 
results observed.  
Within the larger investigation of the DC-SIGN dependence of DENV infection, it was 
observed that blocking did not work (significantly reduce DC-SIGN detection by flow) as 
expected in two out of three B cell experiments, while it was moderately successful with 
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blocking on Raji/DC-SIGN cells. When the receptor was successfully blocked, either in aB or 
Raji/DC-SIGN cells, DC-SIGN was shown to be important for DENV-2 infection. Multiple other 
experiments should be conducted to fully investigate the extent to which DC-SIGN mediates 
DENV infection of B cells. First, the flow cytometry staining protocol should be changed so that 
the antibody against DC-SIGN is added before permeabilization of cells. This would detect only 
surface DC-SIGN, and with blocking using monoclonal anti-DC-SIGN, the total percent of DC-
SIGN positive cells should significantly decrease. Single-cell qRT-PCR could also be used to 
detect the copy number of DC-SIGN in relation to the number of copies of DENV. This would 
investigate if there is a minimum number of DC-SIGN molecules needed per cell for infection.  
Both tested serotypes of DENV (1 and 2) do not infect rB, indicating that rB may not be a 
natural target for DENV infection. Further experiments need to be done on rB with other 
serotypes of DENV (DENV-3 and DENV-4) before making a statement about if they are truly 
not infected by DENV. DENV-1 infects neither resting nor aB. In this regard, this serotype 
differs from DENV-2, which infects aB. Since the blood donors used for the experiments were 
the same, and DC-SIGN expression did not significantly differ between resting and aB, the 
reason for the difference in infection of aB between serotypes remains unclear. I show that DC-
SIGN is important for DENV-2 infection of aB, but it is highly likely that one or more other 
receptors are a part of the infection of aB. Trypsinization of cells before infection would 
establish if the infection of aB is due to virus:receptor interactions, or whether the cells are 
nonspecifically taking up the virus.  
This research is novel since it uses purified primary resting and aB as a target for DENV 
infection. One paper
48
 has shown infection in purified resting B cells.  Others who have 
researched DENV infection in vitro have used pools of cells – either splenic mononuclear cells47 
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or peripheral blood mononuclear cells
46 – have not found B cells to be a target for infection. The 
circulating PBMCs would contain rB, while B cells in the spleen are transitional B cells
79
. Since 
rB cells typically express low levels of DC-SIGN, my finding that DENV-1 and DENV-2 do not 
infect rB is expected, while it contradicts Lin et al’s paper. Lin et al used laboratory-adapted 
strains of virus passaged on  Aedes albopictus C6/36 cells, as I did in this thesis.  
The literature has not yet reflected infection of DENV within the secondary lymphoid 
organs, where the majority of aB would be found. My research is novel in this respect, and I 
have found that DENV-2 infects aB, and that DC-SIGN is important in this infection.  
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6.0  FUTURE DIRECTIONS 
In order to fully validate the results described here, several issues need to be considered. First, 
the blocking of DC-SIGN using a monoclonal antibody should be validated. Another vial for the 
antibody should be used, and the affinity of the antibody for DC-SIGN should be established on 
Raji/DC-SIGN cells before use on B lymphocytes.  
With regards to the infection of cells, performing infection with UV-inactivated DENV 
would allow for the investigation as to whether cells are nonspecifically picking up virus. 
Performing infection on trypsinized cells, thus removing all of the proteins from the surface of 
cells, would also investigate if there were other receptors aiding in the endocytosis of the virus.  
The infection of cells needs to be analyzed by other methods than ones reliant on 
fluorescence. Numerous methods
80 81 82
 have been published for the quantification of DENV by 
qRT-PCR, and using primers specific for the negative strand genome would allow for 
quantification of the replicative genome.  
Given the negative findings, I believe it can be concluded that neither DENV-2 nor 
DENV-1 infects rB. Infection of aB by DENV-2 should be further investigated using many 
additional blood donors, and it may be worthwhile to extend the investigation to DENV-1 and 
DENV-4 infection.  
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